Ghassan Abou-Alfa says serafnib is currently the only first-line treatment approved for HCC based on the SHARP trial, where the treatment showed improved survival in patients from 7.9 months to 10.7 months.
Ghassan Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, talks about first- and second-line treatments for hepatocellular carcinoma (HCC). He says sorafenib is currently the only first-line treatment approved for HCC based on the SHARP trial, where the treatment showed improved survival in patients from 7.9 months to 10.7 months.
Abou-Alfa says he finds it interesting that second-line therapies are already being investigated despite there not being many options for first-line treatments. He says nivolumab and pembrolizumab may have a place in the treatment of HCC.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More